|
|
Exosomal Drug Delivery
|
1R44CA221487-01
|
$719,680
|
$719,680
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
2R44CA162629-02A1
|
$1,154,726
|
$1,154,726
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
1R44CA221539-01
|
$1,206,955
|
$398,295
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
|
Personalized precision dosing of biologic therapies in oncology
|
1R44CA217336-01A1
|
$759,813
|
$759,813
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
|
Feasibility of predicting AML response to induction chemotherapy
|
1R43CA221473-01
|
$299,999
|
$299,999
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS, LLC
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
1R44CA224460-01
|
$299,805
|
$299,805
|
Daunch, William
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-05
|
$346,525
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-21
|
$380,585
|
$125,593
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
$364,614
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-20
|
$483,169
|
$483,169
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-18
|
$417,500
|
$417,500
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Therapeutic TRPA1 Mechanism-Based Treatment of Chemotherapeutic-Induced Neuropathic Pain
|
1R43CA210759-01A1
|
$291,147
|
$291,147
|
HERZ, JEFF
|
ALGOMEDIX, INC.
|
|
|
Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma
|
5R42CA153845-03
|
$772,615
|
$772,615
|
SAMPSON, JOHN
|
ANNIAS IMMUNOTHERAPEUTICS, INC.
|
|
|
Development of a Pharmacoprotector for Platinum Toxicities
|
1R43CA206705-01A1
|
$225,000
|
$225,000
|
CHIEN, HUAN-CHIEH
|
APRICITY THERAPEUTICS, INC.
|
|
|
IDO-Expressing Immunoregulatory Dendritic Cells
|
5R01CA103320-14
|
$307,800
|
$307,800
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
|
Chemotherapy-induced MDSCs and antitumor immunity
|
1R01CA215523-01
|
$347,700
|
$347,700
|
ZHOU, GANG
|
AUGUSTA UNIVERSITY
|
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
1R21CA217137-01
|
$209,093
|
$209,093
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS
|
1U01CA214125-01
|
$1,452,478
|
$1,452,478
|
ELLIS, MATTHEW
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer
|
1R01CA211176-01
|
$362,569
|
$362,569
|
ELSEA, SARAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
SPORE in Lymphoma
|
2P50CA126752-11
|
$3,097,657
|
$371,719
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
5R01CA164024-05
|
$319,474
|
$319,474
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Managing chemotherapy induced neuropathy in Cancer patients using ExerGaming
|
5R21CA190933-02
|
$199,119
|
$199,119
|
NAJAFI, BIJAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
$14,200
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
$14,265
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
$14,670
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
$30,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
$390,374
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
$276,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-04
|
$379,294
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-03
|
$473,915
|
$236,958
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-02
|
$352,363
|
$352,363
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
5R01CA197359-03
|
$388,875
|
$388,875
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-10S1
|
$300,000
|
$21,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-02
|
$272,213
|
$136,107
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting microRNAs to eradicate leukemia stem cells
|
1R01CA205247-01A1
|
$434,503
|
$217,252
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
1R01CA213138-01
|
$395,738
|
$395,738
|
M?SCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Pharmacological modulation of epigenetic changes in AML
|
5R01CA102031-12
|
$342,107
|
$171,054
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-03
|
$1
|
$1
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$4,398
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$7,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$146,801
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Complex Role of HSF1 in Breast Cancer
|
5R01CA176326-04
|
$355,719
|
$117,387
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Hyperpolarized NMR for Studies of Cancer Therapies Targeting the Warburg Effect
|
5R01CA169470-05
|
$361,050
|
$180,525
|
GRANT, AARON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting PML for Leukemia Therapy
|
5R01CA142874-07
|
$465,791
|
$232,896
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALL
|
5R01CA193651-03
|
$446,954
|
$446,954
|
GUTIERREZ, ALEJANDRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
|
Novel Role(s) of Nrf2 in the Growth of Post-Transplantation Cancer
|
5R01CA193675-02
|
$411,185
|
$411,185
|
PAL, SOUMITRO
|
BOSTON CHILDREN'S HOSPITAL
|
|
|
Identification of susceptibility to chemotherapy induced peripheral neuropathy using patient stem cell derived sensory neurons
|
1R03CA220219-01
|
$88,500
|
$88,500
|
WOOLF, CLIFFORD
|
BOSTON CHILDREN'S HOSPITAL
|
|
|
Overcoming Tumor Resistance to Chemotherapy with Multiscale Diffuse and Nonlinear Imaging
|
1F99CA223014-01
|
$41,455
|
$41,455
|
KARROBI, KAVON
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Total relevant funding to Chemotherapy for this search: $317,746,569
|
